Anthracycline-induced cardiotoxicity: Cardiac monitoring by continuous wave-doppler ultrasound cardiac output monitoring and correlation to echocardiography

Onkologie

Volumn 35, Issue 5, 2012, Pages 241-246

  Geiger, Sandra ^a   Stemmler, Hans Joachim ^a   Suhl, Patricia ^a   Stieber, Petra ^b   Lange, Veronika ^a   Baur, Dorothee ^a   Hausmann, Andreas ^a   Tischer, Johanna ^a   Horster, Sophia ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anthracyclines; Cardiotoxicity; CW Doppler; Hs Troponin T; NT pro BNP; Ultrasound; USCOM

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BIOLOGICAL MARKER; DAUNORUBICIN; DOXORUBICIN; MITOXANTRONE; TRASTUZUMAB; TROPONIN T;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTINUOUS WAVE DOPPLER ULTRASOUND CARDIAC OUTPUT MONITORING; CORRELATION ANALYSIS; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMATOLOGIC MALIGNANCY; HEMODYNAMIC MONITORING; HEMODYNAMIC PARAMETERS; HUMAN; MALE; MECHANICAL PROBE; MONITOR; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PILOT STUDY; PROTEIN BLOOD LEVEL; SOLID TUMOR; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84862070288     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000338335     Document Type: Article

References (31)

1. Jain D: Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000;7:53-62.
2. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P: Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502-3508.
3. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT: Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999;25:237-247.
4. Elliott P: Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006;33:S2-7.
5. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R: The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Associa-tion of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914-1931.
6. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R: The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the american heart association, the American College of Cardiology, and the European Ssociety of Cardiology. Circulation 2007;116:2216-2233.
7. Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davidson TW, Davis JL, Douglas PS, Gillam LD: ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on clinical application of echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997;95:1686-1744.
8. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC, Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography). Circulation 2003;108:1146-1162.
9. Urek R, Cubrilo-Turek M: [Natriuretic peptides in clinical practice]. Acta Med Croatica 2008;62:53-56.
10. Mueller C: Comparison of the diagnostic accuracy of BNP and NT-proBNP in acute and chronic heart failure. Clin Chem 2007;53:1719-1720; author reply 1720-1711.
11. Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP: The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007;137:4-12.
12. Mueller T, Gegenhuber A, Poelz W, Haltmayer M: Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91:606-612.
13. Kinnunen P, Vuolteenaho O, Ruskoaho H: Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993;132:1961-1970.
14. Rademaker MT, Richards AM: Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 2005; 108:23-36.
15. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H: B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: Comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006;47:742-748.
16. Gustafsson F, Steensgaard-Hansen F, Badskjaer J, Poulsen AH, Corell P, Hildebrandt P: Diagnostic and prognostic performance of N-terminal proBNP in primary care patients with suspected heart failure. J Card Fail 2005;11:S15-20.
17. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481.
18. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754.
19. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710-715.
20. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36:517-522.
21. Koh E, Nakamura T, Takahashi H: Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004;68:163-167.
22. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD: Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 2002;20: 1677-1682.
23. Knobloch K, Tepe J, Lichtinghagen R, Luck HJ, Vogt PM: Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol 2008; 125:113-115.
24. Knobloch K, Tepe J, Rossner D, Lichtinghagen R, Luck HJ, Busch KH, Vogt PM: Combined NT-pro-BNP and CW-doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapy. Int J Cardiol 2008;128:316-325.
25. van Lelyveld-Haas LE, van Zanten AR, Borm GF, Tjan DH: Clinical validation of the non-invasive cardiac output monitor USCOM-1a in critically ill patients. Eur J Anaesthesiol 2008;25:917-924.
26. Tan HL, Pinder M, Parsons R, Roberts B, van Heerden PV: Clinical evaluation of uscom ultrasonic cardiac output monitor in cardiac surgical patients in intensive care unit. Br J Anaesth 2005; 94:287-291.
27. Stemmler HJ, Weigert O, Grüner N, Tschöp K, Lange V, Parhofer KG: Non-invasive hemodynamic monitoring in critically ill patients: Experience with the USCOM device. Intensivmed 2007;44:366-371.
28. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, Lipshultz SE: Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116:144-147.
29. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.
30. Dey I, Sprivulis P: Emergency physicians can reliably assess emergency department patient cardiac output using the uscom continuous wave doppler cardiac output monitor. Emerg Med Australas 2005;17:193-199.
31. Knobloch K, Hubrich V, Rohmann P, Lupkemann M, Gerich T, Krettek C, Phillips R: Feasibility of preclinical cardiac output and systemic vascular resistance in hems in thoracic pain-the ultrasonic cardiac output monitor. Air Med J 2006;25:270-275.